| P50 | author | James Whitehorn | Q88282835 |
| | Bridget Wills | Q30112202 |
| | Cameron P. Simmons | Q37392993 |
| | Pei-Yong Shi | Q59435668 |
| P2093 | author name string | M Cristina Cassetti | |
| | Katherine L Anders | |
| | Sophie Yacoub | |
| | Vinh Chau Nguyen Van | |
| | Louis R Macareo | |
| P2860 | cites work | Statins for the primary prevention of cardiovascular disease | Q24201513 |
| | Dengue | Q24570132 |
| | The global distribution and burden of dengue | Q24628768 |
| | Should hydroxyethyl starch solutions be totally banned? | Q26859356 |
| | Randomized, Placebo-Controlled Trial of Nonpegylated and Pegylated Forms of Recombinant Human Alpha Interferon 2a for Suppression of Dengue Virus Viremia in Rhesus Monkeys | Q27472702 |
| | An adenosine nucleoside inhibitor of dengue virus | Q27490481 |
| | Dengue virus-induced hemorrhage in a nonhuman primate model | Q27491021 |
| | Clinical and Virological Features of Dengue in Vietnamese Infants | Q27491351 |
| | The structural basis for serotype-specific neutralization of dengue virus by a human antibody | Q27681306 |
| | Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis | Q28269708 |
| | A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults | Q28475036 |
| | Dengue prevention and 35 years of vector control in Singapore | Q28656305 |
| | Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial | Q29616259 |
| | Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome | Q30320030 |
| | Monitoring the microcirculation in the critically ill patient: current methods and future approaches. | Q30986824 |
| | Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria | Q33303521 |
| | Statins for infection and sepsis: a systematic review of the clinical evidence | Q33319066 |
| | Recovery of endothelial function in severe falciparum malaria: relationship with improvement in plasma L-arginine and blood lactate concentrations | Q33349599 |
| | Preventive transfusion in dengue shock syndrome–is it necessary? | Q33357597 |
| | Thrombocytopenia associated with dengue hemorrhagic fever responds to intravenous administration of anti-D (Rh(0)-D) immune globulin | Q33374870 |
| | Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection. | Q33378095 |
| | Lack of efficacy of prophylactic platelet transfusion for severe thrombocytopenia in adults with acute uncomplicated dengue infection | Q33383747 |
| | Prospective observational study of low thresholds for platelet transfusion in adult dengue patients | Q33383873 |
| | Oral calcium administration attenuates thrombocytopenia in patients with dengue fever. Report of a pilot study | Q33385087 |
| | Efficacy of low dose dexamethasone in severe thrombocytopenia caused by dengue fever: a placebo controlled study | Q33386433 |
| | Prophylactic platelets in dengue: survey responses highlight lack of an evidence base | Q33402058 |
| | Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial | Q33402687 |
| | Effectiveness of platelet transfusion in dengue Fever: a randomized controlled trial | Q33411723 |
| | Inhibition of dengue virus by targeting viral NS4B protein | Q34002195 |
| | Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug | Q34246661 |
| | A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients | Q34288828 |
| | Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial | Q34422058 |
| | Therapeutics for dengue: recommendations for design and conduct of early-phase clinical trials | Q34431491 |
| | Comparison of three fluid solutions for resuscitation in dengue shock syndrome | Q34447478 |
| | Modulation of cytokine and cytokine receptor/antagonist by treatment with doxycycline and tetracycline in patients with dengue fever | Q34726827 |
| | Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection | Q34995301 |
| | Corticosteroids for dengue - why don't they work? | Q35071222 |
| | Association between statins given in hospital and mortality in pneumonia patients | Q35777702 |
| | Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus | Q35893162 |
| | Selective inhibitors of hepatitis C virus replication | Q36537226 |
| | Endothelial function and dysfunction: testing and clinical relevance | Q36758044 |
| | Host and viral features of human dengue cases shape the population of infected and infectious Aedes aegypti mosquitoes | Q36895627 |
| | Clinical characteristics of Dengue shock syndrome in Vietnamese children: a 10-year prospective study in a single hospital | Q37272298 |
| | Sepsis-associated microvascular dysfunction measured by peripheral arterial tonometry: an observational study | Q37443105 |
| | Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir | Q37547347 |
| | The pathogenesis of dengue | Q37904027 |
| | Animal models of dengue virus infection | Q37987131 |
| | Nuclear trafficking of proteins from RNA viruses: potential target for antivirals? | Q38023068 |
| | Lovastatin for adult patients with dengue: protocol for a randomised controlled trial | Q38056781 |
| | Ten years of dengue drug discovery: progress and prospects | Q38146430 |
| | Use of pentoxifylline in treatment of children with dengue hemorrhagic fever. | Q38424814 |
| | Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade | Q38663807 |
| | Fluid replacement in dengue shock syndrome: a randomized, double-blind comparison of four intravenous-fluid regimens | Q38979772 |
| | Testing antiviral compounds in a dengue mouse model | Q39131336 |
| | Dengue human infection model: re-establishing a tool for understanding dengue immunology and advancing vaccine development | Q39521661 |
| | Development of clinical decision rules to predict recurrent shock in dengue | Q40226338 |
| | An iminosugar with potent inhibition of dengue virus infection in vivo | Q40258618 |
| | Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines | Q40265040 |
| | Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. | Q40278537 |
| | Common marmoset (Callithrix jacchus) as a primate model of dengue virus infection: development of high levels of viraemia and demonstration of protective immunity | Q40320854 |
| | The use of homeopathic combination remedy for dengue fever symptoms: a pilot RCT in Honduras. | Q40460064 |
| | Risk factors for hemorrhage in severe dengue infections | Q40581664 |
| | Acute management of dengue shock syndrome: a randomized double-blind comparison of 4 intravenous fluid regimens in the first hour | Q40609089 |
| | The differentiation state of monocytic cells affects their susceptibility to infection and the effects of infection by dengue virus | Q40696219 |
| | Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection | Q40910994 |
| | Change in age pattern of persons with dengue, northeastern Brazil | Q42952948 |
| | Effects of fluids on microvascular perfusion in patients with severe sepsis | Q43956709 |
| | Microvascular blood flow is altered in patients with sepsis | Q44045816 |
| | Effects of hydrocortisone on microcirculatory alterations in patients with septic shock | Q46072006 |
| | Spotlight issue: Microcirculation—from a clinical perspective. | Q51633782 |
| P275 | copyright license | Creative Commons CC0 License | Q6938433 |
| P6216 | copyright status | public domain | Q19652 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dengue fever | Q30953 |
| | Dengue virus | Q476209 |
| | chemoprophylaxis | Q1069606 |
| | infectious disease | Q18123741 |
| | RNA virus infectious disease | Q18967413 |
| | biomedical investigative technique | Q66648976 |
| | antiviral agent | Q40207875 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | e3025 | |
| P577 | publication date | 2014-08-01 | |
| P1433 | published in | PLoS Neglected Tropical Diseases | Q3359737 |
| P1476 | title | Dengue therapeutics, chemoprophylaxis, and allied tools: state of the art and future directions | |
| P478 | volume | 8 | |